Chonnam Med J.  2014 Aug;50(2):37-44. 10.4068/cmj.2014.50.2.37.

Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections

• Kim UJ
• Kim HK
• An JH
• Cho SK
• Park KH
• Jang HC

• KMID: 2172157
• DOI: http://doi.org/10.4068/cmj.2014.50.2.37

Abstract

Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomial pathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limits the available therapeutic agents, makes the infection difficult to treat, and is associated with a greater risk of death. In this review, we provide an update on the epidemiology, resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.

Keyword

Acinetobacter baumannii; Colistin; Drug therapy

MeSH Terms

Acinetobacter
Acinetobacter baumannii
Acinetobacter Infections*
Colistin
Critical Illness
Drug Therapy
Epidemiology*
Humans
Infection Control
Critical Care
Colistin